Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. health center
Show results for
Products
Services
Software
Training
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Health Center Articles & Analysis

215 news found

Caresyntax and Sheba ARC Sign Agreement to Develop the Future Model for Surgical Innovation

Caresyntax and Sheba ARC Sign Agreement to Develop the Future Model for Surgical Innovation

The partnership will also work to establish a worldwide collaborative network of prominent hospitals, surgery centers, surgeons, and health organizations to share best practices to inform the continuous development of the ARC Surgical Innovation Model. ...

ByCaresyntax


FDA Establishes New Medical Device Category: FDA Authorization Now Required to Market UV Robots to Healthcare Facilities

FDA Establishes New Medical Device Category: FDA Authorization Now Required to Market UV Robots to Healthcare Facilities

Many of the world’s leading hospitals, including HonorHealth, Mayo Clinic, MD Anderson Cancer Center, Ochsner Health System, Stanford Health Care and Texas Health Resources use LightStrike robots as part of their comprehensive disinfection strategy. ...

ByXenex Disinfection Services Inc.


Forward-looking Pharma Companies Are Increasingly Embracing Millennial Values

Forward-looking Pharma Companies Are Increasingly Embracing Millennial Values

They want to become part of the companies that have gone green and those that care about the people in their communities. 4.Provide benefits According to a recent Transamerica Center for Health Studies (TCHS) survey, 21% of Millennials delay seeking treatment when they are sick. ...

ByBrio Group


ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology

ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology

“ This clinical trial was sponsored by the National Institutes of Health’s (NIH) National Center for Complementary and Integrative Health (NCCIH).* Further information can be found at ...

ByEntero Therapeutics, Inc.


Oligomerix Announces Issuance of Key U.S. Patent for Lead Tau-Targeting Candidate OLX-07010 to Treat Neurodegenerative Diseases

Oligomerix Announces Issuance of Key U.S. Patent for Lead Tau-Targeting Candidate OLX-07010 to Treat Neurodegenerative Diseases

Oligomerix is headquartered at the Westchester Park Center in White Plains, New York and has lab facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of ...

ByOligomerix, Inc.


Oligomerix Announces Series B Extension Raise of $2.7 Million to Support Phase 1 Clinical Development

Oligomerix Announces Series B Extension Raise of $2.7 Million to Support Phase 1 Clinical Development

Oligomerix is headquartered at the Westchester Park Center in White Plains, New York and has lab facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of ...

ByOligomerix, Inc.


Oligomerix Presents Data on Lead Program at Clinical Trials on Alzheimer’s Disease (CTAD) Conference and Society for Neuroscience Meeting

Oligomerix Presents Data on Lead Program at Clinical Trials on Alzheimer’s Disease (CTAD) Conference and Society for Neuroscience Meeting

Oligomerix is headquartered at the Westchester Park Center in White Plains, New York and has lab facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of ...

ByOligomerix, Inc.


Third Pole Therapeutics Receives $32M Strategic Equity Investment to Accelerate its Tankless Inhaled Nitric Oxide (iNO) Platform

Third Pole Therapeutics Receives $32M Strategic Equity Investment to Accelerate its Tankless Inhaled Nitric Oxide (iNO) Platform

Third Pole’s product development has been generously supported by awards from the National Heart, Lung, and Blood Institute of the National Institutes of Health and the National Center for Advancing Translational Sciences of the National Institutes of Health. ...

ByThird Pole Therapeutics, Inc.


Iterative Health Partners with Gastro Health to Accelerate Clinical Research in Gastroenterology Through Artificial Intelligence

Iterative Health Partners with Gastro Health to Accelerate Clinical Research in Gastroenterology Through Artificial Intelligence

Iterative Health, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with Gastro Health, a national leading medical group specializing in digestive and liver health, to bring its AI Recruitment (AIR) technology to Gastro Health’s practices. This strategic partnership ...

ByIterative Health, Inc.


ASH 2022: Cellworks Biosimulation Study Reveals Biomarkers that Predict Response to Hypomethylating Agents and Patient Survival in MDS

ASH 2022: Cellworks Biosimulation Study Reveals Biomarkers that Predict Response to Hypomethylating Agents and Patient Survival in MDS

Guido Marcucci, MD, Chair and Professor, Department of Hematologic Malignancies Translational Science, Director, Gehr; Family Center for Leukemia Research, Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; and Co-Principal Investigator of the study. ...

ByCellworks Research India Private Limited


Digital Diagnostics Named to the 2022 CB Insights’ Digital Health 150 List

Digital Diagnostics Named to the 2022 CB Insights’ Digital Health 150 List

Coralville, Iowa December 7, 2022 — Digital Diagnostics – a leading AI diagnostics company on a mission to transform global healthcare – is a recipient of CB Insights’ fourth-annual Digital Health 150. The list recognizes the 150 most promising private digital health companies of 2022. ...

ByDigital Diagnostics Inc.


Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS) that Demonstrate Elacestrant’s PFS Increases with Duration of Prior CDK4/6i in ER+, HER2- in Metastatic Setting

Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS) that Demonstrate Elacestrant’s PFS Increases with Duration of Prior CDK4/6i in ER+, HER2- in Metastatic Setting

Virginia Kaklamani, MD, DSc, breast medical oncologist and professor of medicine, UT Health San Antonio, MD Anderson Cancer Center, commented, “These results show that when used as a single agent, elacestrant provided mPFS up to 8.6 months, based on the duration of previous CDK4/6 inhibitor therapy, with a manageable safety profile and the convenience of an ...

ByThe Menarini Group


Oligomerix Presents Data from IND-Enabling Studies on Clinical Candidate at Clinical Trials on Alzheimer’s Disease (CTAD) and Neuroscience 2022 Meetings

Oligomerix Presents Data from IND-Enabling Studies on Clinical Candidate at Clinical Trials on Alzheimer’s Disease (CTAD) and Neuroscience 2022 Meetings

“We have been working closely with FDA and our funder, the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH), to finalize our protocol for our first-in-human study, and we look forward to initiating our Phase 1a study of OLX-07010 in the coming ...

ByOligomerix, Inc.


xCures Joins Big Names in Aetion’s New Initiative

xCures Joins Big Names in Aetion’s New Initiative

” Other partners joining xCures in building this relationship with Aetion include AbbVie, Amgen, AstraZeneca, Bayer, Baylor College of Medicine, Brigham and Women’s Hospital and Harvard Medical School, ConcertAI, Duke-Margolis Center for Health Policy, Friends of Cancer Research, Gilead, Loopback Analytics, Pfizer, Reagan-Udall Foundation, Tempus, ...

ByxCures


Live Webinar by MedAxiom Features Best Practices Using Daxor’s Blood Volume Analysis (BVA-100) to Improve Heart Failure Outcomes & Reduce Costs

Live Webinar by MedAxiom Features Best Practices Using Daxor’s Blood Volume Analysis (BVA-100) to Improve Heart Failure Outcomes & Reduce Costs

Jefferies, M.D., MPH, University of Tennessee Health Science Center, Memphis, Tennessee, Timothy Manzone, M.D. Former Section Chief Nuclear Medicine, ChristianaCare, Newark, Delaware, and James Kreiner, MHA, Director Cardiovascular Operations, Prisma Richland, Columbia, South Carolina. ...

ByDaxor Corporation


1st MitraClip Procedure Guided by 4D Performed at UC Davis Health

1st MitraClip Procedure Guided by 4D Performed at UC Davis Health

“I am honored to work with the innovative team at UC Davis Health,” said EchoPixel founder and CEO Sergio Aguirre. “I look forward to continue expanding these and other relationships as practitioners increasingly recognize the value in solutions like ...

ByEchoPixel, Inc.


Synbiotic Health Announces the Expansion of their R&D and Commercial Capabilities with the Acquisition of a New Facility in Madison, Wisconsin

Synbiotic Health Announces the Expansion of their R&D and Commercial Capabilities with the Acquisition of a New Facility in Madison, Wisconsin

In addition to the R&D and commercial activities that will be operational at launch, the facility is expected to expand in the future with the addition of new services and capabilities that will provide added value to the dietary supplement market. About Synbiotic Health Synbiotic Health was founded in 2018 by four microbiome research scientists to develop ...

BySynbiotic Health


Experienced Healthcare Leader Laurie Smith Joins Inspirata as Vice President of Product Strategy for Clinical Trial Matching

Experienced Healthcare Leader Laurie Smith Joins Inspirata as Vice President of Product Strategy for Clinical Trial Matching

Most recently, Laurie was a Vice President for Clinical Research Services at Roswell Park Comprehensive Cancer Center. Prior to that, she had served for three decades at prominent healthcare institutions, such as AMITA Health, Rush University Medical Center, University of Chicago, Siteman Cancer Center Clinical Trials Office, and ...

ByInspirata, Inc


Oligomerix Awarded $2.49M from NIH to Further Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy Candidate OLX-07010

Oligomerix Awarded $2.49M from NIH to Further Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy Candidate OLX-07010

Award to support Phase 1b studies to evaluate tau self-association small molecule inhibitor In August, company announced a $3.35M grant from NIH to support a Phase 1a clinical trial Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced an award of $2.49 ...

ByOligomerix, Inc.


New Data Shows Heart Failure Treatment Guided by Daxor’s BVA-100 Lowers Hospital Length of Stay by 55%

New Data Shows Heart Failure Treatment Guided by Daxor’s BVA-100 Lowers Hospital Length of Stay by 55%

Jefferies, University of Tennessee Health Science Center, Memphis, TN. We are pleased to announce that Daxor had another strong presence at this year’s HFSA,” said Jonathan Feldschuh, Chief Scientific Officer of Daxor Corporation. ...

ByDaxor Corporation

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT